Skip to main content
. 2009 Jul 24;17(2):73–79. doi: 10.1038/cgt.2009.50

Figure 4.

Figure 4

Immune Response parameters after i.v. injection of vvDD (GM-CSF−) or JX-963 (GM-CSF+). (a) Antivaccinia neutralizing antibody development over time. (b) Induction of VX2 tumor-targeting cytotoxic T lymphocytes (CTL) following i.v. administration of vvDD or JX-963 (*, P<0.05 between groups); E/T ratio, ratio of effector cells to target cells.